Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same
CA 2263503 C · Owner: Adler, Adam · Inventors: Adler, Adam; Rosenberg, Steven A.; Pardoll, Drew M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention pertains to a method of treating or protecting against melanoma that comprises (a) obtaining a melanoma cell line that expresses one or more shared immunodominant melanoma antigens (b) modifying the melanoma cell line , to render it capable of producing an increased level of a citokyne relative to the unmodified cell line, and (c) administering the melanoma cell line to a mammalian host that has melanoma or is at risk for developing melanoma. Preferably the melanoma cell line is allogenic and is not MHC-matched to the host.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 4, 1997 and granted April 10, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 4, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 4, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.